Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-20
    E.g., 2018-10-20

Archive Search

2 results
12:00 AM, Nov 14, 2013  |  BC Innovations | Distillery Therapeutics

Indication: Neurology

V1a receptor antagonist, SRX251, is in Phase I to treat dysmenorrhea. Roche's V1a receptor antagonist, RG7314
12:00 AM, Apr 19, 2012  |  BC Innovations | Strategy

Building tools against autism

in autistic patients. Roche also has another autism compound, the vasopressin 1a (V1a) receptor antagonist RG7314